Reuters logo
BRIEF-Cempra reports Q2 loss per share $0.23
August 9, 2017 / 12:50 PM / in 4 months

BRIEF-Cempra reports Q2 loss per share $0.23

Aug 9 (Reuters) - Cempra Inc

* Cempra provides corporate update and reports second quarter 2017 financial results

* Q2 loss per share $0.23

* Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S

* Cempra Inc - ‍In Q1 of 2017, met with FDA to discuss solithromycin complete response letter (CRL)​

* Cempra Inc - ‍FDA reiterated their request for additional clinical safety data prior to approval for solithromycin​

* Cempra Inc - ‍FDA has stated that phase 3 trials provided evidence that oral and intravenous (IV) solithromycin are effective for treatment of CABP​

* Cempra Inc - ‍FDA has not requested further efficacy data to support co’s response to CRL for solithromycin​

* Cempra Inc - ‍Continue to advance manufacturing activities for solithromycin at Uquifa

* Cempra - Engaged with potential government and industry partners to identify non-dilutive funding to support execution of solithromycin study ​

* Cempra Inc - ‍Expect to reduce second half 2017 expenses by more than 70 percent compared to second half of 2016​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below